AMRN Files for Rehearing
Subscribers,
On Oct 2, 2020, AMRN filed a Petition for rehearing with the Federal Circuit. The attached video discusses this Petition and why it is highly unlikely to be granted. In the next segment, the video presentation explains why the market reacted so aggressively to this litigation even though it relates to the super high triglyceride "Marine Trial Patents" and not AMRN's patents that relate more directly to the cardiovascular risk reduction indication supported by the Reduce-It trial. Finally, I provide a preview of what will likely be my next post/presentation, which relates to whether this is the end of the road for AMRN's ability to use its patent estate to protect U.S. Vascepa sales from generic competition.
Manny
Disclaimer:
*Emanuel "Manny" Vacchiano, J.D., PhD., is a licensed U.S. patent attorney.
No attorney-client relationship is established by your purchase of this product. If you would like to inquire about a possible legal representation by Dr. Vacchiano and his law firm, Double Helix Law, LLC, please contact Dr. Vacchiano at mannyv@doublehelixlaw.com.
You are reminded as indicated in our terms, that in exchange for getting this analysis at a very reasonable price you agree not to share it with others.
Information provided on ampbiotechresearch.com and by Manny Vacchiano, Amp Biotech Research, LLC, or any of its consultants on the Amp web site and in any of our reports, products and services are for information only and are not investment or legal advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.
#AMRN #Vascepa #triglycerides #cardiovascular #ANDA #patents